Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Xu Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6920-0375; OpenAlex author ID A5071800484. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
58
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 4 papers · 2023: 5 papers · 2024: 2 papers · 2025: 2 papers

Papers 16

  1. Assessment of tertiary lymphoid structures via 18F-FDG PET/CT scan in patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s00262-025-04205-x↗
  2. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  3. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid applic… Co-author DOI 10.1016/j.canlet.2024.216741↗
  4. Efficacy of Hyperthermic Intraperitoneal Chemotherapy Alone for Diffuse Peritoneal Carcinomatosis from Pancreatic Adenocarcinoma: A Single-Centre Retrospective… Co-author DOI 10.21203/rs.3.rs-4011964/v1↗
  5. Assessment of stromal SCD-induced drug resistance of PDAC using 3D-printed zPDX model chips. Co-author DOI 10.1016/j.isci.2022.105723↗
  6. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance. Co-author DOI 10.1136/jitc-2023-006698↗
  7. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12876-023-02748-w↗
  8. Characterization of Estrogen Receptors in Pancreatic Adenocarcinoma with Tertiary Lymphoid Structures. Co-author DOI 10.3390/cancers15030828↗
  9. Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol30020126↗
  10. Neoadjuvant chemotherapy endows CD9 with prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer. Co-author DOI 10.1002/jcla.24517↗
  11. Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41389-022-00411-9↗
  12. Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2022/7353572↗
  13. Molecular signatures of tumor progression in pancreatic adenocarcinoma identified by energy metabolism characteristics. Co-author DOI 10.1186/s12885-022-09487-3↗
  14. Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. Co-author DOI 10.3390/cancers13153678↗
  15. Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment. Last author DOI 10.3791/59507↗
  16. U0126 inhibits pancreatic cancer progression via the KRAS signaling pathway in a zebrafish xenotransplantation model. Last author DOI 10.3892/or.2015.4019↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 12 shared papers, 2021–2025 · strength 1.99
  2. Xuan Lin · 10 shared papers, 2021–2025 · strength 1.66
  3. Xuan Zou · 9 shared papers, 2022–2025 · strength 1.56
  4. Yusheng Chen · 8 shared papers, 2022–2025 · strength 1.40
  5. Chen Liu · 8 shared papers, 2022–2025 · strength 1.39
  6. He Cheng · 7 shared papers, 2022–2025 · strength 1.20
  7. Zhengjie Dai · 7 shared papers, 2022–2024 · strength 1.14
  8. Yesiboli Tasiheng · 6 shared papers, 2022–2024 · strength 0.94
  9. Mingjian Ma · 5 shared papers, 2023–2025 · strength 0.91
  10. Yu Yan · 3 shared papers, 2023–2025 · strength 0.56
  11. Guopei Luo · 3 shared papers, 2022–2025 · strength 0.45
  12. Yunzhen Qian · 3 shared papers, 2022–2023 · strength 0.44
  13. Chen Liu · 2 shared papers, 2023–2024 · strength 0.36
  14. Yitao Gong · 2 shared papers, 2022 · strength 0.27
  15. Heli Gao · 2 shared papers, 2021–2022 · strength 0.25
  16. Wuhu Zhang · 2 shared papers, 2021–2022 · strength 0.25
  17. Huaxiang Xu · 2 shared papers, 2021–2022 · strength 0.25
  18. Wenquan Wang · 2 shared papers, 2021–2022 · strength 0.25
  19. Xuan Han · 2 shared papers, 2021–2022 · strength 0.25
  20. Jiang Long · 2 shared papers, 2019–2023 · strength 0.24
  21. Yu Liu · 1 shared paper, 2024 · strength 0.20
  22. Bing Peng · 1 shared paper, 2025 · strength 0.19
  23. Jin Xu · 1 shared paper, 2025 · strength 0.19
  24. He Cheng · 1 shared paper, 2025 · strength 0.19
  25. Weiding Wu · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.